KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Operating Leases (2018 - 2026)

Biogen has reported Operating Leases over the past 9 years, most recently at $273.4 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 15.46% year-over-year to $273.4 million; the TTM value through Mar 2026 reached $273.4 million, down 15.46%, while the annual FY2025 figure was $290.4 million, 31.0% down from the prior year.
  • Operating Leases for Q1 2026 was $273.4 million at Biogen, down from $290.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $490.3 million in Q4 2023 and troughed at $273.4 million in Q1 2026.
  • A 5-year average of $351.6 million and a median of $327.0 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: soared 30.21% in 2022 and later crashed 31.0% in 2025.
  • Year by year, Operating Leases stood at $430.2 million in 2022, then grew by 13.97% to $490.3 million in 2023, then fell by 14.15% to $420.9 million in 2024, then crashed by 31.0% to $290.4 million in 2025, then decreased by 5.85% to $273.4 million in 2026.
  • Business Quant data shows Operating Leases for BIIB at $273.4 million in Q1 2026, $290.4 million in Q4 2025, and $305.0 million in Q3 2025.